PSMA radioligand therapy: what to know

A radioligand has two linked parts: one recognises PSMA on a cell, and the other carries radiation. After administration, the compound can attach to PSMA-bearing cells and release radiation nearby. Lutetium-177 is one material used in some PSMA-directed treatments. Suitability depends on scan findings, previous treatments, blood counts, kidney function, and the overall treatment plan.

The therapy is systemic, meaning it travels through the bloodstream rather than being placed only in one tumour. It is given in a specialist setting, where the team monitors you and provides instructions about fluids, bathroom use, and contact with other people.

Your team may arrange blood tests and imaging before each treatment decision. Tell them about kidney disease, bone-marrow problems, medicines, allergies, pregnancy, and breastfeeding. Ask how to manage food, fluids, regular medicines, and transport home. Follow radiation-safety instructions carefully and keep follow-up appointments so blood counts, kidneys, and symptoms can be assessed.

Possible effects vary. The team may discuss tiredness, nausea, dry mouth, changes in blood counts, and kidney-related concerns, along with ways to manage them. Do not change treatment or medicines without guidance from your oncology team.

Contact your oncology service promptly for fever, chills, persistent vomiting, unusual bleeding, marked bruising, reduced urine, or worsening weakness. Seek urgent help for breathing difficulty, collapse, confusion, or severe allergic symptoms. Use the written radiation-safety contact instructions supplied by your treatment centre.

Ask how PSMA expression was assessed, why this therapy is being considered, what alternatives exist, how treatment is scheduled, and which blood or kidney results matter. Ask what precautions apply at home and who to call about side effects.